REGENXBIO has completed dosing in the confirmatory study of RGX-202, an AAV-delivered microdystrophin gene therapy for the treatment of Duchenne. The company is on track to initiate a Biologics License Application (BLA) under the accelerated approval pathway in Q3 2026, for a potential approval by the US FDA in the second half on 2027.
Press release: REGENXBIO press release – RGX-202 – 24Jun2026
Community letter to be added.
The post REGENXBIO completes dosing in Duchenne gene therapy confirmation study; planning BLA submission to FDA in Q3 2026 appeared first on CureDuchenne.